Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OlympiaN: Olaparib and Durvalumab in Early Stage Breast Cancer
NCT05498155Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2022
- Primary completion
- Nov 2024
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 9
01
Overview
A Phase 2 trial of olaparib, durvalumab in breast cancer, sponsored by AstraZeneca. Started Nov 2022; status: completed.
02
Drugs
olaparibdurvalumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05498155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05498155.